Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Alternative Donor Transplantation Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Donor/Recipient Mixed Chimerism Does Not Predict Graft Failure in Children with Beta-Thalassemia Given Allogeneic Cord Blood Transplantation from An HLA-Identical Related DonorClinically Relevant Abstract

Daniela Lisini1*, Marco Zecca1*, Giovanna Giorgiani1*, Daniela Montagna2*, Rosaria Cristantielli1*, Massimo Labirio1*, Pierangela Grignani3*, Carlo Previderé3*, Giovanni Amendola4*, Angela Mastronuzzi1*, Rita Maccario1* and Franco Locatelli1

1Oncoematologia Pediatrica, Laboratorio di Immunologia dei Trapianti, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
2Dipartimento di Scienze Pediatriche, Università degli Studi di Pavia, Pavia, Italy
3Laboratorio di Ematologia Forense, Istituto di Medicina Legale, Università degli Studi di Pavia, Pavia, Italy
4Unità di Pediatria, Ospedale di Nocera Inferiore, Nocera Inferiore, Italy

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related MortalityClinically Relevant Abstract

Eneida R. Nemecek, MD1, Mohamed L. Sorror, MD, MS2*, Kristine C. Doney, MD2, Bart Lee Scott, MD2, Tibor J. Kovacsovics, MD1, Richard Thomas Maziarz, MD1, Ann E Woolfrey, MD2*, Jean Sanders, MD2, Paul V. O'Donnell2*, Katherine Guthrie, PhD2* and H. Joachim Deeg, MD2

1Oregon Health & Science University, Portland, OR
2Clinical Research Division, Fred Hutchinson Cancer Research Center & University of Washington, Seattle, WA

Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II StudyClinically Relevant Abstract

Wolfgang A Bethge, MD1*, Stephanie von Harsdorf, MD2*, Martin Bornhauser, MD3*, Dietrich Beelen, MD4*, Matthias Stelljes, MD5*, Rainer Schwerdtfeger, MD6, Lutz Uharek7*, Birgit Federmann, MD1*, Christoph Faul, MD1*, Wichard Vogel, MD1*, Helmut Dittmann, MD8*, Lothar Kanz, MD9 and Donald Bunjes, MD2*

1Hematology & Oncology, Medical Center University of Tuebingen, Tuebingen, Germany
2Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
3University Hospital Dresden, Dresden, Germany
4Department of Bone Marrow Transplantation, University Hospital Essen, Germany
5Hematology & Oncology, Medical Center University of Muenster, Muenster, Germany
6Centre for hematopoietic cell transplantation, German Diagnostic Clinic, Wiesbaden, Germany
7Medical Clinic III - Hematology and Oncology, Charité University Medicine Berlin, Germany
8Nuclear Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
9Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany

Cord Blood (CB) Extends Transplant Access to Racial and Ethnic Minorities: A Prospective Study of 309 Unrelated Searches in Patients with High-Risk Hematologic MalignanciesClinically Relevant Abstract

Sinda S. Lee*, Andromachi Scaradavou, MD, Rebecca M. Hawke*, Kathleen A. Webb*, Deborah S. Wells*, Michelle Abboud*, Esperanza B. Papadopoulos, MD*, Nancy A. Kernan, MD and Juliet N. Barker, MBBS

Memorial Sloan-Kettering Cancer Center, New York, NY

The Comparison Between Matched Related Donor and Alternative Donor for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acquired Aplastic Anemia: KSBMT2007-02 Study

Hawk Kim1, Hong Hoe Koo, MD, PhD2, Hoon Kook, MD3, Byung Soo Kim, MD4*, Sung Hyun Kim, MD, PhD5, Hack-Ki Kim, MD6*, Hyeoung Joon Kim, MD7, Sung Hwa Bae, MD8, Sang Kyun Sohn9, Ho-Jin Shin, MD10, Hyo Seop Ahn, MD, PhD11*, Jong-Ho Won, MD, PhD12, Sung-Soo Yoon, MD, PhD13, Young-Ho Lee, MD, PhD14*, Dae-Chul Jeong, MD, PhD15, Deog-Yeon Jo16, Young-Don Joo17, Min Kyoung Kim, MD18, Myung Soo Hyun, MD, PhD18* and Kyoo Hyung Lee, MD19

1Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, South Korea
2Dept. of Pediatrics, Sungkyunkwan Univ., School of Med., Seoul, South Korea
3Dept. of Pediatrics, Chonnam National Univ., Hwasun-gun, Chonnam, South Korea
4Korea University Hospital
5Dept. of Hem.-Onc., Internal Med., Dong-A University Hospital, Pusan, South Korea
6The Catholic University of Korea St. Marry's Hospital
7Chonnam University Hospital, Kwangju, South Korea
8Internal Medicine, Daegu Catholic University Hospital, Daegu, South Korea
9The Korean Society of Hematology, Seoul, South Korea
10Dept. of Hematology, Stanford University, Cupertino, CA
11Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea
12Div. of Hem./Onc., Dept. of Med., Soon Chun Hyang Univ. Hosp., Seoul, South Korea
13Div. of Internal Medicine, Seoul National Univ. Hosp., Seoul, South Korea
14Department of Pediatrics, Hanyang University Medical Center, Seoul, South Korea
15Pediatrics, Our Lady of Mercy Hospital, Incheon, South Korea
16CML working party, The Korean Society of Hematology, Seoul, South Korea
17Dept. of Hematology/Oncology Internal Med., Busan Paik Hospital, Inje Univ., Busan, South Korea
18Department of Internal Medicine, Yeungnam University Medical Center, Daegu, South Korea
19hematology, Dept internal Medicine, Asan Medical Center, Seoul, South Korea

Alternate Donor HCT for Fanconi Anemia (FA): Results of a Total Body Irradiation (TBI) Dose De-Escalation Study

Margaret L. MacMillan, MD, Bruce R. Blazar, MD*, Todd DeFor, MS*, Linan Ma, MSPH*, Jakub Tolar, MD*, Heather Zierhut, MS* and John E. Wagner, MD*

University Of Minnesota, Minneapolis, MN

Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDSClinically Relevant Abstract

Gheath Alatrash1*, Borje S. Andersson1*, Matteo Pelosini2*, Gabrila Rondon1*, Muzaffar H. Qazilbash1*, Sergio Giralt1*, Leandro de Padua Silva1, Chitra Hosing1, Partow Kebriaei1, Weiqing Zhang1*, Rima Saliba1*, Richard E. Champlin1* and Marcos De Lima1

1Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
2Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Pisa, Italy

Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post-Transplant Outcomes in Patients with AMLClinically Relevant Abstract

Gheath Alatrash1*, Matteo Pelosini2*, Rima M Saliba1*, Gabriela Rondon1*, Weiqing Zhang1*, Sergio Giralt1*, Partow Kebriaei1*, Amin Alousi1*, Issa F Khouri1*, Richard E Champlin1* and Marcos De Lima1

1Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
2Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Pisa, Italy

The Effect of the CASP8 -6526N Del Promoter Polymorphism on Outcome in T-Cell Depleted Unrelated Donor Haemopoetic Stem Cell Transplants (HSCT)

Suchitra Krishnamurthy, MRCP, FRCPath1*, Bronwen E. Shaw, MBChB, PhD, MRCP, MRCPath2*, J. L Byrne3*, C. Seedhouse4*, Neema P Mayor5*, A. J Madrigal5* and Nigel H. Russell, MD6

1Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
2Haemato.-Oncology, Royal Marsden Hosp., Sutton, Surrey
3Centre for Clinical Haematology, Nottingham University Hospital, Nottingham
4Academic Haematology, Nottingham University Hospital, Nottingham, United Kingdom
5Haematology, UCL Cancer Institute, London, United Kingdom
6Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, ARRAY(0xc1c3fa4)

Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR

Daniela Pende, PhD1*, Stefania Marcenaro, PhD2*, Michela Falco, PhD3*, Stefania Martini1*, Maria Ester Bernardo, MD4, Daniela Montagna, PhD5*, Elisa Romeo, PhD3*, Myriam Martinetti, PhD6*, Rita Maccario, PhD7*, Maria Cristina Mingari, PhD2*, Lorenzo Moretta, MD8*, Franco Locatelli, MD4* and Alessandro Moretta, MD2*

1Immunologia, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
2Dipartimento di Medicina Sperimentale, University of Genova, Genova, Italy
3Immunologia Clinica e Sperimentale, Istituto G. Gaslini, Genova, Italy
4Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
5Dipartimento di Scienze Pediatriche Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
6Laboratorio di Tipizzazione Tissutale, Fondazione IRCCS Policlinico, University of Pavia, Pavia, Italy
7Laboratorio di Trapianto di Midollo Osseo e Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
8Dipartimento di Medicina Sperimentale, University of Genova and Istituto G. Gaslini, Genova, Italy

Perfect Engraftment after Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Transplantation in Severe Aplastic Anemia: Phase II Prospective Multi-Center Study in KoreaClinically Relevant Abstract

Hyoung Jin Kang1, Hee Young Shin2*, Jun Eun Park3*, Young Tak Lim4*, Nak Gyun Chung5*, Bin Cho5*, Hack Ki Kim5*, Sun Young Kim6*, Young Ho Lee7*, Keon Hee Yoo8*, Ki Woong Sung8*, Hong Hoe Koo9*, Ho Joon Im10*, Jong Jin Seo10*, Sang Kyu Park11* and Hyo Seop Ahn1*

1Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea
2Seoul National University College of Medicine, Seoul, South Korea
3Ajou University School of Medicine
4Pusan National University, School of Medicine
5College of Medicine, The Catholic University of Korea
6Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, South Korea
7Hanyang University College of Medicine
8Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
9Sungkyunkwan University School of Medicine, Samsung Medical Center
10University of Ulsan College of Medicine, Asan Medical Center
11University of Ulsan College of Medicine, Ulsan University Hospital

Contribution of HLA Incompatibility on Clinical Outcomes of CBT in Patients with MDS Including Secondary AML in Japan: Multivariate Analysis Using Competing Risk Regression ModelClinically Relevant Abstract

Satoshi Takahashi, MD1, Takuhiro Yamaguchi, PhD2*, Maki Monna-Ooiwa1*, Shuichi Taniguchi, MD3*, Hisashi Sakamaki, MD, PhD4*, Takeshi Morii, MD5*, Yoshihisa Nagatoshi, MD6*, Nobuyuki Aotsuka, MD7*, Shunichi Kato, MD8*, Minoko Takanashi, MD9*, Tokiko Nagamura, MD10*, Hiroshi Azuma, PhD11*, Shunro Kai, MD12*, Koji Kato, MD13 and Shigetaka Asano, MD14

1Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Sciece, Univ. of Tokyo, Tokyo, Japan
2Department of Clinical Trial Data Management, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
3Department of Hematology, Toranomon Hospital, Tokyo, Japan
4Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
5Department of Hematology, Nara Medical University, Nara, Japan
6Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan
7Narita Red Cross Hospital, Narita, Japan
8Tokai University, Isehara, Japan
9The Metro Tokyo Red Cross Cord Blood Bank, Tokyo, Japan
10Institute of Medical Sciece, Univ. of Tokyo, Tokyo, Japan
11Hokkaido Cord Blood Bank, Sapporo, Japan
12Hyogo Cord Blood Bank, Nishinomiya, Japan
13Department of Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
14School of Science and Engineering, Waseda University, Tokyo, Japan

Mismatching at HLA-DPB1 Is Not Associated with Survival in Patients with Acquired Aplastic Anemia Who Receive Unrelated Bone Marrow Transplantation

Hiroshi Yagasaki, MD1*, Seiji Kojima, MD1*, Shunichi Kato, MD2*, Koji Kato, MD3, Hiromasa Yabe, MD4*, Hisashi Sakamaki, MD5, Takakazu Kawase, MD6*, Masahiro Tsuchida, MD7, Hisato Kigasawa, MD8*, Yasuo Morishima, MD6* and Yoshihisa Kodera, MD9*

1Pediatrics, Nagoya University, Nagoya, Japan
2Tokai University, Isehara, Japan
3Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
4Cell Transplantation, Tokai University, Isehara, Japan
5Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
6Aichi cancer center, Nagoya, Japan
7Ibaraki childrens hospital, Mito, Japan
8Kanagawa childrens hospital, Yokohama, Japan
9Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Tansplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) StudyClinically Relevant Abstract

India Sisler, MD1*, Jennifer Domm, MD1, Robin Ryan2*, John E. Levine, MD3, Michael Pulsipher, MD4, Paul R. Haut, MD5, Kirk R. Schultz, MD6, Tatsuki Koyama1*, Elizabeth Koehler1* and Haydar Frangoul1

1Vanderbilt University Medical Center, Nashville, TN
2Childrens Mercy Hospital, Kansas City, MO
3Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI
4University of Utah Medical Center, Salt Lake City, UT
5Riley Hospital for Children, Indianapolis, IN
6B.C. Children's Hospital, Vancouver, BC, Canada

Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel Disease-Associated Markers with Gvhd or Other Outcomes in T-Replete, Unrelated Donor Transplantation Facilitated by the NMDP

Yume Nguyen, MD1*, Abed Al-Lehibi, MD1*, Elizabeth Gorbe, BA1*, Ellen Li, PhD1*, Michael D Haagenson, MS2*, Tao Wang, PhD3*, Stephen R Spellman, MS4*, Stephanie J. Lee, MD, MPH5 and Nicholas O Davidson, MD, DSc1*

1Washington University School of Medicine, St. Louis, MO
2Center for International Blood and Marrow Transplant Research, Minneapolis, MN
3Medical College of Wisconsin, Milwaukee, WI
4National Marrow Donor Program, Minneapolis, MN
5Fred Hutchinson Cancer Research Center, Seattle, WA

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Adam J Mead1*, Kirsty J Thomson2*, Emma C Morris3, Ronjon Chakraverty4*, David C. Linch, FRCP5, Stephen Mackinnon, MD4 and Karl S Peggs6*

1Haematology, UCL, London, United Kingdom
2Dept. Haematology, University College London, Hertfordshire, United Kingdom
3Dept. Haematology, University College London, United Kingdom
4Deptartment of Haematology, Royal Free and Univ. College, London
5Department of Hematology, University College London, London, ARRAY(0xc117b58)
6Haematology, University College London, London, United Kingdom

Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

Hans Jochem Kolb, MD1, Iris Bigalke2*, Dominik Termeer2*, Susanne Fritsch3*, Wolfgang Hill1*, Belinda Simoes4*, Andreas Hausmann1*, Christine Falk2*, Raymund Buhmann1*, Johanna Tischer1* and Georg Ledderose1*

13. Medizinische Klinik, Transplantationseinheit, München, Germany
2Institute for Molecular Immunology, Helmholtz Zentrum München, Muenchen, Germany
33. Medizinische Klinik, Transplantationseinheit, München, Germany
4Hospital das Clinicas, Faculdade de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil

Effects of Recipients' Body Weight and Total Nucleated Cell Dose on Outcomes of Unrelated Bone Marrow Transplantation: Analysis of Clinical Data of 3,114 Leukemia Patients from the Database of the Japan Marrow Donor ProgramClinically Relevant Abstract

Takuya Yamashita1*, Hideki Akiyama1, Kazuteru Ohashi1, Makoto Onizuka2*, Shin-ichiro Mori3*, Hiroshi Sao4*, Koichi Miyamura5* and Hisashi Sakamaki1*

1Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
2Department of Hematology, Oncology and Reumatology, Tokai University School of Medicine, Japan
3Stem Cell Transplantation Div., National Cancer Ctr. Hosp., Japan
4Department of Hematology, Meitetsu Hospital, Japan
5Department of Hematology, Japanese Red Cross Nagoya First Hospital, Japan

TGFB1 Functional Polymorphisms: Impact on Outcome in Allogeneic Unrelated Donor Haematopoietic Stem Cell TransplantationClinically Relevant Abstract

Mariano Berro, MD1*, Louise Cooke2*, Neema P Mayor3*, Gustavo Kusminsky, MD4*, Steven G.E. Marsh, PhD5*, J. Alejandro Madrigal, MD, PhD6 and Bronwen E. Shaw, MBChB, PhD, MRCP, MRCPath7*

1Anthony Nolan Research Institute, Anthony Nolan Trust, London, London, United Kingdom
2Anthony Nolan Research Institute, London, Anthony Nolan Trust, London, London, United Kingdom
3Haematology, Anthony Nolan Trust, London, UCL Cancer Institute, Royal Free Campus, London, London, United Kingdom
4Servicio de Hematologia, Hospital Universitario Austral, Buenos Aires Argentina, Buenos Aires, Argentina
5Anthony Nolan Research Institute, Anthony Nolan Trust, London, Anthony Nolan Trust, London, UCL Cancer Institute, Royal Free Campus, London, London, United Kingdom
6Anthony Nolan Trust, London, UCL Cancer Institute, Royal Free Campus, London, London
7Haemato.-Oncology, Anthony Nolan Trust, London, Royal Marsden Hospital, London, UK, Sutton, Surrey

Identifying Amino Acid Substitution Positions Associated with Day 100 Survival in Unrelated Donor Stem Cell Transplant Using Random Forest Analysis

Susana Marino, MD, PhD1*, Shang Lin, PhD1*, Martin Maiers, MS2*, Michael D Haagenson, MS3*, Stephen R Spellman, MS2*, Stephanie J. Lee, MD, MPH4, Tao Wang, PhD5*, John Klein, PhD5* and Koen Van Besien, MD1*

1University of Chicago Medical Center, Chicago, IL
2National Marrow Donor Program, Minneapolis, MN
3Center for International Blood and Marrow Transplant Research, Minneapolis, MN
4Fred Hutchinson Cancer Research Center, Seattle, WA
5Medical College of Wisconsin, Milwaukee, WI

The Presence of Moderate to High Donor-Specific Anti-HLA Antibody Titers Is Associated with a High Risk of Graft Failure in Haploidentical Stem Cell Transplantation

Stefan O Ciurea, MD1, Marcos De Lima, MD1, Pedro Cano, PhD2*, Martin Korbling, MD1*, John McMannis, PhD3*, Sergio A Giralt, MD1*, Borje S Andersson, MD, PhD1, Elizabeth J. Shpall, MD1, Richard E Champlin, MD1* and Marcelo Fernandez-Vina, PhD2*

1Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX
2HLA Laboratory, The University of Texas M. D. Anderson Cancer Center, Houston
3Cell Processing Laboratory, The University of Texas M. D. Anderson Cancer Center, Houston

Theoretical Availability of UCBT in High Body Weight Patients Who Received Haplo-SCT for High Risk Haematological Malignancies: Results of the Simulation of Search through BMDW According to International GuidelinesClinically Relevant Abstract

Maria Teresa Lupo Stanghellini, MD1*, Annalisa Ruggeri, MD1*, Jacopo Peccatori, MD1*, Massimo Bernardi, MD1*, Consuelo Corti, MD1*, Chiara Bonini, MD2, Claudio Bordignon, MD3* and Fabio Ciceri, MD1*

1Hematology and Bone Marrow Transplantation Unit, IRCCS H San Raffaele, Milano, Italy
2Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, Milan, Italy
3Univeristy Vita-Salute San Raffaele Scientific Institute, Milan, Italy

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical DonorsClinically Relevant Abstract

Elizabeth Shima Rich, MD, PhD1, Andrew Artz, MD, MS1, Theodore Karrison, PhD2*, Amittha Wickrema, PhD1, Loren Joseph, PhD3*, Lucy Godley, MD, PhD1, Olatoyosi Odenike, MD1, Justin Kline, MD1, Paula del Cerro, RN1*, John M Cunningham, MD4, Richard A. Larson, MD1, Wendy Stock, MD1 and Koen van Besien, MD1*

1Section of Hematology/Oncology, University of Chicago, Chicago, IL
2Department of Health Studies, University of Chicago, Chicago, IL
3Department of Pathology, University of Chicago, Chicago, IL
4Department of Pediatrics, University of Chicago, Chicago

*signifies non-member of ASH